Moxifloxacina Krka

Moxifloxacin, the active ingredient in Moxifloxacina Krka, is a fluoroquinolone presented as an oral tablet for systemic use. It treats a variety of bacterial infections, including community‑acquired pneumonia, acute bacterial sinusitis, exacerbations of chronic bronchitis, skin and skin‑structure infections, and complicated intra‑abdominal infections, in adult and appropriate pediatric patients.

GNH USA supplies Moxifloxacina Krka as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies, and clinics across global markets while adhering to stringent quality standards and regulatory requirements.

Moxifloxacina Krka (moxifloxacin) is indicated for several bacterial infections affecting the respiratory, sinus, skin, and intra‑abdominal systems.

Community‑acquired pneumonia: effective eradication of the causative pathogens in adult patients. Acute bacterial sinusitis: resolves infection and alleviates sinus inflammation. Acute bacterial exacerbation of chronic bronchitis: reduces bacterial load and improves lung function. Skin and skin‑structure infections: treats cellulitis, abscesses, and related conditions. Complicated intra‑abdominal infections: provides coverage against mixed aerobic and anaerobic organisms.

Moxifloxacina Krka may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea - Diarrhea - Headache - Dizziness - Abdominal pain - Rash

Serious or Rare Side Effects: - Tendon rupture or inflammation - QT interval prolongation and cardiac arrhythmias - Severe allergic reactions such as anaphylaxis - Clostridioides difficile‑associated colitis - Hepatic dysfunction or jaundice - Stevens‑Johnson syndrome and toxic epidermal necrolysis

Before prescribing Moxifloxacina Krka, clinicians should consider several precautionary measures to ensure safe use.

Renal or hepatic impairment: adjust monitoring and consider dose modification. History of tendon disorders: avoid use due to increased risk of tendon rupture. QT prolongation risk: perform ECG monitoring in patients with cardiac risk factors. Concomitant use of antacids containing aluminum or magnesium: separate administration by at least 2 hours. Pregnancy and lactation: use only if potential benefits justify potential risks. Store at room temperature: keep in the original container, protect from moisture and light.

Moxifloxacina Krka can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Co‑administration with other fluoroquinolones: additive toxicity. - Use with drugs that prolong the QT interval (e.g., macrolides, antiarrhythmics): heightened risk of cardiac arrhythmias. - Combination with systemic corticosteroids: increased risk of tendon rupture.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: reduce absorption; separate dosing by ≥2 hours. - Warfarin: may enhance anticoagulant effect; monitor INR closely. - Theophylline: may increase serum levels; observe for toxicity.